Orbus Pharma offers pharmaceutical research, manufacturing, packaging, and warehousing services on a contract basis for other drug companies. Orbus Pharma specializes in oral suspension and generic pharmaceutical products. The company serves the North American, European, and other international markets. It develops formulations of existing drugs using proprietary delivery systems and then provides out-licensing and contract manufacturing services for the products. Orbus has agreed to allow China-based pharmaceutical firm Nanjing Sanhome Pharmaceutical Co. to acquire a majority of its shares.

Interleukin Genetics, Inc. was founded in 1986 and is headquartered in Waltham, Massachusetts. Interleukin Genetics, Inc., together with its subsidiaries, focuses on developing, acquiring, and commercializing personalized health products that help individuals improve and maintain their health through preventive measures in the United States and internationally. It conducts, researches, develops, markets, and sells genetic test panels primarily in inflammatory and metabolic areas to provide insight into health, wellness, and disease. The company markets and distributes genetic tests under the GENSONA brand, through a strategic partnership with Alticor; and PST tests through sales and marketing partners to dentists and periodontists. It offers genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

Savient Pharmaceuticals, Inc. company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey. Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers.

Pfizer decided to put a Cork in it, the pharmaceutical giant made Ireland one of the world's largest manufacturers and exporters of pharmaceuticals. Pfizer Ireland Pharmaceuticals is part of the Pfizer Global Manufacturing division. Parent company Pfizer began operating in Ireland in 1969 with a citric acid manufacturing plant and now operates about a dozen Irish plants. Its manufacturing facilities are involved in the development, formulation, and bulk manufacture of human pharmaceuticals (especially cardiovascular drugs) and animal health care products, as well as sterile pharmaceutical products and active pharmaceutical ingredients.

Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Garden of Life, Inc. Company manufactures and supplies nutritional supplements, specialty food items, and personal care products. Its supplements include weight management, digestive health, and immune-system support products. The company's Original Medicine division produces nutritional products for distribution by health practitioners; its other lines are sold through natural foods retailers. Many of Garden of Life's products are based on a program called The Maker's Diet which was created by company founder and chairman Jordan Rubin in 2000 after overcoming Crohn's disease. Garden of Life has agreed to be acquired by Atrium Innovations.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.